5-(hydroxymethyl)-3-isoxazolecarboxamide | 890095-65-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(hydroxymethyl)-3-isoxazolecarboxamide
• 英文别名: 3-carbamoylisoxazol-5-ylmethanol；5-(Hydroxymethyl)-1,2-oxazole-3-carboxamide
• CAS: 890095-65-5
• 化学式: C₅H₆N₂O₃
• mdl: MFCD08273508
• 分子量: 142.114
• InChiKey: CACIAMRXJXVWNS-UHFFFAOYSA-N

物化性质

• 沸点：
  405.7±35.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  89.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(hydroxymethyl)-3-isoxazolecarboxamide 在 吡啶 、 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 6.17h， 生成 (3-carbamoylisoxazol-5-yl)methyl (3aR,5r,6aS)-5-(4-fluoro-1,3-benzothiazol-2-yl)-5-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
  参考文献：
  名称：

  CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

  摘要：

  该发明涉及一般式（I）的化合物，其中：R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；m、n、o和p独立地是从0到3的数字；A是共价键、氧原子、C1-6-烷基烯基团或—O—C1-6-烷基烯基团，其中一个端是氧原子与R1基团结合，而另一个端是烷基烯基团与双环化合物的碳结合；R1是可选择取代的芳基或杂环芳基；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；其中这些化合物可以处于碱性或酸性盐的状态。该发明可用于治疗学。

  公开号：

  US20120095040A1

文献信息

• DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20110319381A1

  公开（公告）日：2011-12-29

  The invention relates to a compound of the general formula (I) in which R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy, NR 8 R 9 group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C 1-8 -alkylene group; R 1 is an optionally substituted aryl or heteroaryl group; R 3 is a hydrogen or fluorine atom or a C 1-6 -alkyl group or a trifluoromethyl group; R 4 is an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof.

  该发明涉及一般式（I）的化合物，其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基、NR8R9基团中的一种；m、n、o和p分别是等于0、1、2或3的整数；A是共价键或C1-8-烷基烯基团；R1是可选择取代的芳基或杂环芳基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；所述化合物为盐基或酸加合盐形式。该发明还涉及其治疗用途。
• CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：Abouabdellah Ahmed

  公开号：US20120015950A1

  公开（公告）日：2012-01-19

  Compound corresponding to general formula (I): in which R 2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy or NR 8 R 9 group; n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 or 2; A is a covalent bond or a C 1-8 -alkylene group; R 1 is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, cinnolinyl or naphthyridinyl group, this group being optionally substituted; R 3 is a hydrogen or fluorine atom, a C 1-6 -alkyl group or a tritluoromethyl group; R 4 is a group selected from furanyl, pyrrolyl, thienyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, oxadiazolyl, thiadiazolyl, imidazole, triazolyl, tetrazolyl, oxazolone, oxazolidinone, isoxazolone, isoxazolidinone, isothiazolone, isothiazolidinone, imidazolone, imidazolidinone, pyrazolone, pyrazolidinone, oxadiazolone, thiadiazolone and triazolone, this group being optionally substituted; in the form of a base or of an addition salt with an acid. Therapeutic use.

  与一般式(I)对应的化合物：其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基或NR8R9基团；n是等于1、2或3的整数，m是等于1或2的整数；A是共价键或C1-8-烷基烯基团；R1是苯基、吡啶基、吡啉基、嘧啶基、吡嗪基、三嗪基、萘基、喹啉基、异喹啉基、邻苯二嗪基、喹唑啉基、喹喜啉基、喹啉基、咔啉基或萘啉基团，该基团可选择性地被取代；R3是氢原子或氟原子、C1-6-烷基或三氟甲基基团；R4是从呋喃基、吡咯基、噻吩基、异噻唑基、噁唑基、异噁唑基、吡唑基、噁二唑基、噻二唑基、咪唑基、三唑基、四唑基、噁唑酮、噁唑烷酮、异噁唑酮、异噁唑烷酮、异噻唑酮、异噻唑烷酮、咪唑酮、咪唑烷酮、吡唑酮、吡唑烷酮、噁二唑酮、噻二唑酮和三唑酮中选择的基团，该基团可选择性地被取代；以盐酸形式或酸的加合盐形式存在。治疗用途。
• [EN] ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION<br/>[FR] DÉRIVÉS CARBAMATES ALKYL-HÉTÉROCYCLIQUES, LEUR PRÉPARATION ET LEUR APPLICATION THÉRAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2011089550A1

  公开（公告）日：2011-07-28

  The invention relates to compounds corresponding to the general formula (I) : in which R2 represents a hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or -NR8R9; n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; A represents a covalent bond, an oxygen, a C1-6-alkylene or -O-C1-6-alkylene; R1 represents a phenyl or a heterocycle which is optionally substituted; R3 represents a hydrogen, fluorine, C1-6-alkyl or trifluoromethyl; R4 represents an optionally substituted 5-membered heterocycle; in the form of the base or of an addition salt with an acid; with the exclusion of 5-methylisoxazol-3-ylmethyl 4-hydroxy-4- (4- chlorophenyl) piperidine-1-carboxylate. The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.

  本发明涉及与通式（I）相对应的化合物： 其中，R2表示氢、氟、羟基、氰基、三氟甲基、C1-6烷基、C1-6烷氧基或-NR8R9；n和m分别表示等于1、2或3的整数，其中m+n的总和最多等于5；A表示共价键、氧、C1-6-烷基亚甲基或-O-C1-6-烷基亚甲基；R1表示苯基或可选取代的杂环；R3表示氢、氟、C1-6烷基或三氟甲基；R4表示可选取代的5-成员杂环；以碱或酸的加成盐的形式存在。 本发明还涉及制备通式（I）化合物的方法、包含它们的组合物以及它们的治疗应用，但不包括5-甲基异噁唑-3-基甲基4-羟基-4-（4-氯苯基）哌啶-1-羧酸酯。
• ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
  申请人：Abouabdellah Ahmed

  公开号：US20120295909A1

  公开（公告）日：2012-11-22

  The invention relates to compounds corresponding to the general formula (I): in which R 2 represents a hydrogen, fluorine, hydroxyl, cyano, trifluoromethyl, C 1-6 -alkyl, C 1-6 -alkoxy or —NR 8 R 9 ; n and m represent, independently of one another, an integer equal to 1, 2 or 3, it being understood that the sum m+n is at most equal to 5; A represents a covalent bond, an oxygen, a C 1-6 -alkylene or —O—C 1-6 -alkylene; R 1 represents a phenyl or a heterocycle which is optionally substituted; R 3 represents a hydrogen, fluorine, C 1-6 -alkyl or trifluoromethyl; R 4 represents an optionally substituted 5-membered heterocycle; in the form of the base or of an addition salt with an acid; with the exclusion of 5-methylisoxazol-3-ylmethyl 4-hydroxy-4-(4-chlorophenyl)piperidine-1-carboxylate. The invention also relates to a process for the preparation of the compounds of formula (I), to compositions comprising them and to their therapeutic application.

  本发明涉及与通式（I）相对应的化合物： 其中R2代表氢、氟、羟基、氰基、三氟甲基、C1-6烷基、C1-6烷氧基或—NR8R9；n和m独立地表示为1、2或3的整数，其中m+n的总和最大为5；A代表共价键、氧、C1-6烷基亚基或—O—C1-6烷基亚基；R1代表苯基或可选取代的杂环；R3代表氢、氟、C1-6烷基或三氟甲基；R4代表可选取代的5元杂环；以其碱式或酸盐形式存在；但排除5-甲基异噁唑-3-基甲基4-羟基-4-(4-氯苯基)哌啶-1-羧酸酯。 本发明还涉及制备通式（I）化合物的方法，包括它们的组合物和它们的治疗应用。
• Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
  申请人：Abouabdellah Ahmed

  公开号：US08889702B2

  公开（公告）日：2014-11-18

  The invention relates to a compound of the general formula (I) in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, NR8R9 group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C1-8-alkylene group; R1 is an optionally substituted aryl or heteroaryl group; R3 is a hydrogen or fluorine atom or a C1-6-alkyl group or a trifluoromethyl group; R4 is an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof.

  该发明涉及通式（I）的化合物，其中R2是氢原子或氟原子或羟基、氰基、三氟甲基、C1-6-烷基、C1-6-烷氧基、NR8R9基团；m、n、o和p分别是0、1、2或3；A是共价键或C1-8-烷基链；R1是可选择取代的芳基或杂环芳基基团；R3是氢原子或氟原子或C1-6-烷基或三氟甲基基团；R4是可选择取代的5-成员杂环化合物；该化合物以盐酸形式或酸加成盐的形式存在。该发明还涉及其治疗应用。